<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="366047">
  <stage>Registered</stage>
  <submitdate>31/03/2014</submitdate>
  <approvaldate>9/04/2014</approvaldate>
  <actrnumber>ACTRN12614000387628</actrnumber>
  <trial_identification>
    <studytitle>Everolimus for the prevention of calcineurin-inhibitor-induced left ventricular hypertrophy in heart transplantation</studytitle>
    <scientifictitle>An open label randomised study comparing the role of combination of everolimus and low dose tacrolimus with full dose tacrolimus in the prevention of left ventricular hypertrophy in heart transplant recepients.</scientifictitle>
    <utrn>Nil</utrn>
    <trialacronym>RAD-TAC study</trialacronym>
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Left ventricular hypertrophy in heart transplantation</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>RADTAC arm: Everolimus tablets, administered orally, twice daily in combination with low dose tacrolimus, mycophenolate +/- predinsolone, all taken orally, commenced at 3 months post transplantation and continued for at least 9 months. The Everolimus will be started at 0.5mg twice daily and then adjusted according to the plasma level aiming 3-8 mcg/lit. The tacrolimus dose will be started at 0.5mg twice daily and then adjusted according to the plasma levels aiming 2-5mcg/lit. The Mycophenolate dose will 1000-2000mg twice daily and prednisole maintenance dose will be 7.5-10mg daily as per current standard of care for heart transplantation. 
To improve the patient`s adherence to the treatment, they will be asked about the medications and doses they have been taking as well as encouraged to take medications at each clinical visit.
Their adherence will be monitored by checking plasma drug levels at each clinical visit.</interventions>
    <comparator>TAC arm: The current standard treatment in the form of tacrolimus tablets, administered orally, twice daily in combiantion with oral mycophenolate +/- oral predinsolone. The tacrolimus dose will be started at 0.5mg twice daily and then adjusted according to the plasma levels aiming 6-10mcg/lit. The Mycophenolate dose will 1000-2000mg twice daily and prednisole maintenance dose will be 7.5-10mg daily as per current standard of care for heart transplantation. 
</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Drugs</interventioncode>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Left ventricular mass index as measured by cardiac magnetic resonance imaging (CMR) at one year post heart transplantation.</outcome>
      <timepoint>9 months and 33 months (12 months and 36 months post heart transplantation).</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Systemic blood Pressure measured manually with sphygmomanometer.
</outcome>
      <timepoint>9 months and 33 months (12 months and 36 months post heart transplantation).</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Novel measures of fibrosis by CMR and blood markers.</outcome>
      <timepoint>9 months and 33 months (12 months and 36 months post heart transplantation).</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Estimated glomerulatr filtration rate (eGFR).
</outcome>
      <timepoint>9 months and 33 months (12 months and 36 months post heart transplantation).</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Stable orthotopic heart transplant recipients at 3-months after heart transplantation and willingness to provide informed consent.
</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Hemodynamic instability at 10 weeks after transplantation, greater than 2 x 3A rejection or single 3B rejection, ongoing sepsis at 10 weeks after transplantation, ongoing wound dehiscence or infection at 10 weeks after transplantation, end-stage renal failure requiring dialysis at 10 weeks after transplantation, and contraindication to cardiovascular magnetic resonance scanning
</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Allocation is not concealed.</concealment>
    <sequence>Simple randomisation using a randomisation table created by computer software i.e. computerised sequence generation.</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods>We calculated the sample size from LV Mass index Outcome based on CMR data from Grothues et al. Based on a standard deviation of 4.4 g/m2 a study of 30 patients with 2 arms (90%power and alpha error of 0.05) would allow a 5.26g/m2 difference to be detected. To allow for approximately 30% dropout we aim to recruit 40 patients to the study
Statistical methods to be employed include t-tests, analysis of variance, analysis of covariance repeated measures ANOVA as appropriate for parametric data and Mann-Whitney, Wilcoxon Signed Rank, and Friedman tests as appropriate for non-parametric data.</statisticalmethods>
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 0</phase>
    <anticipatedstartdate>16/04/2014</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate>2/04/2015</anticipatedenddate>
    <actualenddate />
    <samplesize>40</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,WA,VIC</recruitmentstate>
    <hospital>St Vincent's Hospital (Darlinghurst) - Darlinghurst</hospital>
    <hospital>The Alfred - Prahran </hospital>
    <hospital>The Prince Charles Hospital - Chermside</hospital>
    <hospital>Royal Perth Hospital - Perth</hospital>
    <postcode>2010 - Darlinghurst</postcode>
    <postcode>3181 - Prahran</postcode>
    <postcode>4032 - Chermside</postcode>
    <postcode>6000 - Perth</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>St. Vincent`s Hospital</primarysponsorname>
    <primarysponsoraddress>390 Victoria street, Darlinghurst, NSW 2010</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>St. Vincents hospital, NSW</fundingname>
      <fundingaddress>390 Victoria street, Darlinghurst, NSW 2010</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary purpose of the study is to assess left ventricular hypertrophy prevention at 1 year after heart transplantation with everolimus in combination with low-dose calcineurin inhibitors compared to full-dose calcineurin inhibitors.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>St. Vincent`s Hospital HREC</ethicname>
      <ethicaddress>St. Vincent`s research office, Level 6 Delacy building,
390 Victoria street, Darlinghurst, NSW 2010</ethicaddress>
      <ethicapprovaldate>10/12/2013</ethicapprovaldate>
      <hrec>HREC/13/SVH/345</hrec>
      <ethicsubmitdate>14/11/2013</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Peter Macdonald</name>
      <address>St. Vincent`s hospital, 390 Victoria street, Darlinghurst, NSW 2010</address>
      <phone>+61-2-83821111</phone>
      <fax />
      <email>pmacdonald@stvincents.com.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Andrew Jabbour</name>
      <address>St. Vincent`s hospital, 390 Victoria street, Darlinghurst, NSW 2010</address>
      <phone>+61-2-83821111</phone>
      <fax />
      <email>ajabbour@stvincents.com.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Andrew Jabbour</name>
      <address>St. Vincent`s hospital, 390 Victoria street, Darlinghurst, NSW 2010</address>
      <phone>+61-2-83821111</phone>
      <fax />
      <email>ajabbour@stvincents.com.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Muhammad Imran</name>
      <address>St. Vincent`s hospital, 390 Victoria street, Darlinghurst, NSW 2010</address>
      <phone>0061-413751201</phone>
      <fax />
      <email>m.imran@victorchang.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>